Kenvue (KVUE) is higher as trading shifts back toward the company’s agreed sale to Kimberly-Clark, a deal that values KVUE at $21.01 per share using the announced cash-and-stock terms ($3.50 cash plus 0.14625 Kimberly-Clark shares per KVUE share). With both companies’ shareholders having already approved the transaction on January 29, 2026, the move reflects renewed expectations the deal ultimately closes and that today’s price still leaves meaningful upside to the stated consideration. (kenvue.com)

After the shareholder vote hurdle, the next gating items are regulatory clearances, including U.S. antitrust review, with closing still framed for the second half of 2026. Any signs the review track remains intact can tighten the arbitrage spread and drive incremental demand for KVUE shares. (sec.gov)

The stock’s discount to the deal value persists because investors are still pricing execution risk: regulatory timing and deal conditions, plus ongoing merger-related disclosure lawsuits that have been filed in multiple jurisdictions. Separate product-liability overhangs tied to talc claims also remain a headline risk for the combined J&J/Kenvue ecosystem, which can widen the spread on negative legal developments. (tipranks.com)

Key near-term watch items are any updates on antitrust/foreign regulatory approvals, additional merger-related SEC communications, and the next earnings date window in mid-May 2026 that could affect standalone fundamentals while the deal is pending. If regulators signal delays, the spread can widen; if clearance milestones land smoothly, KVUE can continue grinding toward the implied takeout value. (sec.gov)